{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T22:33:33Z","timestamp":1793572413958,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Mepolizumab is primarily used in the treatment of asthma, eosinophilic granulomatosis with polyangiitis, eosinophilia syndrome, and chronic rhinitis with nasal polyps. The information about its adverse drug reactions is mainly derived from clinical trials, and there is a shortage of real-world studies with extensive sample sizes. In this study, the U.S. FDA\u2019s Adverse Event Reporting System (FAERS) database was analyzed to evaluate the side effects of mepolizumab. A total of 18,040 reports of mepolizumab-associated adverse events were identified from the FDA Adverse Event Reporting System database. Multiple disproportionality analysis algorithms were used to determine the significance of these AEs. The study identified 198 instances of mepolizumab-induced AEs, including some important AEs not mentioned in the product labeling. The time to onset of adverse reactions was also analyzed, with a median time of 109 days. Most AEs occurred within the first month of mepolizumab use, but some may still occur after 1\u00a0year of treatment. Gender-specific analysis showed different high-risk AEs for females (digestive and neurological side effects) and males (serious adverse effects leading to hospitalization and death). The findings mentioned provide valuable insights on optimizing the use of mepolizumab, enhancing its effectiveness, and minimizing potential side effects. This information will greatly contribute to the practical implementation of the drug in clinical settings.<\/jats:p>","DOI":"10.3389\/fphar.2023.1320458","type":"journal-article","created":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:13:58Z","timestamp":1703132038000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":67,"title":["A real-world pharmacovigilance study of mepolizumab in the FDA adverse event reporting system (FAERS) database"],"prefix":"10.3389","volume":"14","author":[{"given":"Fan","family":"Zou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chengyu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiwei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingyong","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyou","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanbo","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.jaci.2021.06.006","article-title":"COVID-19 risk and outcomes in adult asthmatic patients treated with biologics or systemic corticosteroids: nationwide real-world evidence","volume":"148","author":"Adir","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"103615","DOI":"10.1016\/j.amjoto.2022.103615","article-title":"Adverse events of biological therapy in chronic rhinosinusitis with nasal polyps: a systematic review","volume":"43","author":"Aldajani","year":"2022","journal-title":"Am. J. Otolaryngol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2042098620938595","DOI":"10.1177\/2042098620938595","article-title":"Post marketing surveillance of suspected adverse drug reactions through spontaneous reporting: current status, challenges and the future","volume":"11","author":"Alomar","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B4","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s002280050466","article-title":"A Bayesian neural network method for adverse drug reaction signal generation","volume":"54","author":"Bate","year":"1998","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jaci.2020.05.013","article-title":"ACE2, TMPRSS2, and furin gene expression in the airways of people with asthma-implications for COVID-19","volume":"146","author":"Bradding","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/s0140-6736(10)61380-3","article-title":"Role of viral respiratory infections in asthma and asthma exacerbations","volume":"376","author":"Busse","year":"2010","journal-title":"Lancet"},{"key":"B7","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jaci.2020.05.051","article-title":"Expression of SARS-CoV-2 receptor ACE2 and coincident host response signature varies by asthma inflammatory phenotype","volume":"146","author":"Camiolo","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s40264-020-00911-w","article-title":"Disproportionality analysis for pharmacovigilance signal detection in small databases or subsets: recommendations for limiting false-positive associations","volume":"43","author":"Caster","year":"2020","journal-title":"Drug Saf."},{"key":"B9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jaip.2017.05.001","article-title":"Asthma exacerbations: pathogenesis, prevention, and treatment","volume":"5","author":"Castillo","year":"2017","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1016\/j.celrep.2017.10.110","article-title":"Testosterone attenuates group 2 innate lymphoid cell-mediated airway inflammation","volume":"21","author":"Cephus","year":"2017","journal-title":"Cell Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1016\/s0140-6736(04)16255-7","article-title":"Viral shedding patterns of coronavirus in patients with probable severe acute respiratory syndrome","volume":"363","author":"Cheng","year":"2004","journal-title":"Lancet"},{"key":"B12","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B13","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1016\/s2213-2600(17)30125-x","article-title":"Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial","volume":"5","author":"Chupp","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.jaip.2019.03.022","article-title":"New targeted therapies for uncontrolled asthma","volume":"7","author":"Corren","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B15","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/14740338.2023.2219892","article-title":"An overview of methodological flaws of real-world studies investigating drug safety in the post-marketing setting","volume":"22","author":"Crisafulli","year":"2023","journal-title":"Expert Opin. Drug Saf."},{"key":"B16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1067\/mai.2002.125600","article-title":"Incidence and remission of asthma: a retrospective study on the natural history of asthma in Italy","volume":"110","author":"De Marco","year":"2002","journal-title":"J. Allergy Clin. Immunol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s40264-020-00913-8","article-title":"Sex differences in adverse drug reactions of metformin: a longitudinal survey study","volume":"43","author":"de Vries","year":"2020","journal-title":"Drug Saf."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1007\/s40265-021-01597-9","article-title":"REal worlD effectiveness and safety of mepolizumab in a multicentric Spanish cohort of asthma patients stratified by eosinophils: the REDES study","volume":"81","author":"Domingo Ribas","year":"2021","journal-title":"Drugs"},{"key":"B19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","article-title":"Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports","volume":"10","author":"Evans","year":"2001","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40264-022-01194-z","article-title":"Post-marketing surveillance of CAR-T-cell therapies: analysis of the FDA adverse event reporting system (FAERS) database","volume":"45","author":"Fusaroli","year":"2022","journal-title":"Drug Saf."},{"key":"B21","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s11882-017-0686-1","article-title":"Mechanisms driving gender differences in asthma","volume":"17","author":"Fuseini","year":"2017","journal-title":"Curr. Allergy Asthma Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"4431","DOI":"10.1016\/j.jaip.2021.07.050","article-title":"Safety and efficacy of mepolizumab in hypereosinophilic syndrome: an open-label extension study","volume":"9","author":"Gleich","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B23","doi-asserted-by":"publisher","first-page":"20601","DOI":"10.1038\/s41598-022-23726-4","article-title":"A real-world pharmacovigilance study of FDA adverse event reporting system (FAERS) events for niraparib","volume":"12","author":"Guo","year":"2022","journal-title":"Sci. Rep."},{"key":"B24","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1056\/NEJMoa0808991","article-title":"Mepolizumab and exacerbations of refractory eosinophilic asthma","volume":"360","author":"Haldar","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"B25","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1016\/j.cell.2021.04.019","article-title":"The basic immunology of asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/s2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1979","DOI":"10.1111\/all.13451","article-title":"Immunological and hematological effects of IL-5(R\u03b1)-targeted therapy: an overview","volume":"73","author":"Hassani","year":"2018","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1536097","DOI":"10.1080\/20018525.2018.1536097","article-title":"Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma - a systematic review and meta-analysis","volume":"5","author":"Henriksen","year":"2018","journal-title":"Eur. Clin. Respir. J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"106601","DOI":"10.1016\/j.intimp.2020.106601","article-title":"Colitis following the use of immune checkpoint inhibitors: a real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system","volume":"84","author":"Hu","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/s0140-6736(22)01198-9","article-title":"Mepolizumab for urban children with exacerbation-prone eosinophilic asthma in the USA (MUPPITS-2): a randomised, double-blind, placebo-controlled, parallel-group trial","volume":"400","author":"Jackson","year":"2022","journal-title":"Lancet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.jad.2023.11.025","article-title":"Safety assessment of Brexpiprazole: real-world adverse event analysis from the FAERS database","volume":"346","author":"Jiang","year":"2023","journal-title":"J. Affect. Disord."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1111\/all.15376","article-title":"Airway remodelling rather than cellular infiltration characterizes both type2 cytokine biomarker-high and -low severe asthma","volume":"77","author":"Khalfaoui","year":"2022","journal-title":"Allergy"},{"key":"B33","doi-asserted-by":"publisher","first-page":"2042098620922483","DOI":"10.1177\/2042098620922483","article-title":"Adverse drug reactions reporting in Turkey and barriers: an urgent need for pharmacovigilance education","volume":"11","author":"Khan","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1016\/j.clinthera.2019.07.007","article-title":"Long-term safety and clinical benefit of mepolizumab in patients with the most severe eosinophilic asthma: the COSMEX study","volume":"41","author":"Khurana","year":"2019","journal-title":"Clin. Ther."},{"key":"B36","doi-asserted-by":"publisher","first-page":"162","DOI":"10.5056\/jnm19175","article-title":"A unique case of non-cardiac chest pain caused by mepolizumab: case report and review of the literature","volume":"26","author":"Korbitz","year":"2020","journal-title":"J. Neurogastroenterol. Motil."},{"key":"B37","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1002\/pds.964","article-title":"Comparison of data mining methodologies using Japanese spontaneous reports","volume":"13","author":"Kubota","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B38","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e233161","DOI":"10.1136\/bcr-2019-233161","article-title":"Case of paradoxical adverse response to mepolizumab with mepolizumab-induced alopecia in severe eosinophilic asthma","volume":"13","author":"Nixon","year":"2020","journal-title":"BMJ Case Rep."},{"key":"B40","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40780-018-0109-z","article-title":"Signals of gastroesophageal reflux disease caused by incretin-based drugs: a disproportionality analysis using the Japanese adverse drug event report database","volume":"4","author":"Noguchi","year":"2018","journal-title":"J. Pharm. Health Care Sci."},{"key":"B41","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","article-title":"Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source","volume":"22","author":"Noguchi","year":"2021","journal-title":"Briefings Bioinforma."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/all.15056","article-title":"From DREAM to REALITI-A and beyond: mepolizumab for the treatment of eosinophil-driven diseases","volume":"77","author":"Pavord","year":"2022","journal-title":"Allergy"},{"key":"B44","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1056\/NEJMoa1708208","article-title":"Mepolizumab for eosinophilic chronic obstructive pulmonary disease","volume":"377","author":"Pavord","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/s0140-6736(12)60988-x","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1080\/14740338.2020.1799975","article-title":"A real-world disproportionality analysis of FDA Adverse Event Reporting System (FAERS) events for baricitinib","volume":"19","author":"Peng","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"B47","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1016\/s0140-6736(22)02125-0","article-title":"Asthma","volume":"401","author":"Porsbjerg","year":"2023","journal-title":"Lancet"},{"key":"B48","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.1016\/j.rmed.2007.06.011","article-title":"Outcome and severity of adult onset asthma--report from the obstructive lung disease in northern Sweden studies (OLIN)","volume":"101","author":"R\u00f6nmark","year":"2007","journal-title":"Respir. Med."},{"key":"B49","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1002\/pds.1001","article-title":"The reporting odds ratio and its advantages over the proportional reporting ratio","volume":"13","author":"Rothman","year":"2004","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.jaci.2020.08.037","article-title":"Efficacy and safety of mepolizumab in hypereosinophilic syndrome: a Phase III, randomized, placebo-controlled trial","volume":"146","author":"Roufosse","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B51","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA adverse event reporting system","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int. J. Med. Sci."},{"key":"B52","doi-asserted-by":"publisher","first-page":"e0228544","DOI":"10.1371\/journal.pone.0228544","article-title":"Prevalence and contribution of respiratory viruses in the community to rates of emergency department visits and hospitalizations with respiratory tract infections, chronic obstructive pulmonary disease and asthma","volume":"15","author":"Satia","year":"2020","journal-title":"PLoS One"},{"key":"B53","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.chest.2019.10.009","article-title":"Recent advances in severe asthma from phenotypes to personalized medicine","volume":"157","author":"Schoettler","year":"2020","journal-title":"Chest."},{"key":"B54","doi-asserted-by":"publisher","first-page":"862508","DOI":"10.3389\/fphar.2022.862508","article-title":"Post-marketing safety concerns with secukinumab: a disproportionality analysis of the FDA adverse event reporting system","volume":"13","author":"Shu","year":"","journal-title":"Front. Pharmacol."},{"key":"B55","doi-asserted-by":"publisher","first-page":"789","DOI":"10.2147\/CLEP.S365513","article-title":"A real-world disproportionality analysis of olaparib: data mining of the public version of FDA adverse event reporting system","volume":"14","author":"Shu","year":"","journal-title":"Clin. Epidemiol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"381","DOI":"10.2165\/00002018-200225060-00001","article-title":"Use of screening algorithms and computer systems to efficiently signal higher-than-expected combinations of drugs and events in the US FDA\u2019s spontaneous reports database","volume":"25","author":"Szarfman","year":"2002","journal-title":"Drug Saf."},{"key":"B57","doi-asserted-by":"publisher","first-page":"970066","DOI":"10.3389\/fphar.2022.970066","article-title":"Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: a pharmacovigilance study based on FAERS","volume":"13","author":"Tang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pds.668","article-title":"A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions","volume":"11","author":"van Puijenbroek","year":"2002","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B59","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1056\/NEJMoa1702079","article-title":"Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis","volume":"376","author":"Wechsler","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1200254","DOI":"10.3389\/fphar.2023.1200254","article-title":"A real-world pharmacovigilance analysis of FDA adverse event reporting system database for upadacitinib","volume":"14","author":"Wu","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1129730","DOI":"10.3389\/fphar.2023.1129730","article-title":"Pneumocystis jirovecii pneumonia associated with immune checkpoint inhibitors: a systematic literature review of published case reports and disproportionality analysis based on the FAERS database","volume":"14","author":"Xia","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1016\/j.jaci.2020.08.008","article-title":"Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study","volume":"146","author":"Yang","year":"2020","journal-title":"J. Allergy Clin. Immunol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1016\/j.jaip.2020.09.021","article-title":"Emerging causes of drug-induced anaphylaxis: a review of anaphylaxis-associated reports in the FDA adverse event reporting system (FAERS)","volume":"9","author":"Yu","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B64","doi-asserted-by":"publisher","first-page":"1194545","DOI":"10.3389\/fphar.2023.1194545","article-title":"Safety analysis of pemigatinib leveraging the US Food and Drug administration adverse event reporting system","volume":"14","author":"Zhang","year":"2023","journal-title":"Front. Pharmacol."},{"key":"B65","doi-asserted-by":"publisher","first-page":"103828","DOI":"10.1016\/j.ajp.2023.103828","article-title":"Adverse events of epidiolex: a real-world drug safety surveillance study based on the FDA adverse event reporting system (FAERS) database","volume":"90","author":"Zhou","year":"2023","journal-title":"Asian J. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1320458\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T04:14:02Z","timestamp":1703132042000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1320458\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,21]]},"references-count":65,"alternative-id":["10.3389\/fphar.2023.1320458"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1320458","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,21]]},"article-number":"1320458"}}